CTSO CytoSorbents Corporation

$7.9 +0.96%

176,781 Shares Traded
176,913 Average Volume (last 30 days)

as of February 23, 2018 EST IEX Real-Time Price

Short Pain Metrics

Approximate Amount of Money Shorts Have Lost on the Day: $99.54 thousand
If Intiated on the First, Shorts Have Realized a Year to Date Return of:-19.85%
If Intiated One Month Ago, Shorts Have Realized a Return of:-1.29%
If Initiated Five Days ago, Shorts Have Realized a Return of:-8.65%
Peer Potential Short Squeezes Near Real Time Screener
*Please note the actual returns of shorts could be different as they started from different points

Daily Indicators

Daily Short Pain Indicator [i] - Always Use Fundamentals on EverythingNeutral
200 Day Moving Average Indicator Bullish
50 Day Moving Average Indicator Bullish
52 Week High/Low Indicator Bullish

Short Stats

Short Percent to Float 13.72%
Short Interest1.33 million
Float9.67 million
Short Ratio10.13
Market Cap$225.23 million
Market Maker ActivityDaily Short Volume

News

02-15-2018
CytoSorbents Expands Its Partnership with Biocon to Launch CytoSorb® in Malaysia (PR Newswire)
02-06-2018
CytoSorbents to Present at the 20th Annual BIO CEO & Investor Conference (PR Newswire)
02-01-2018
New Study Demonstrates Improved Hemodynamic Stability After Heart Transplant Surgery using Intraoperative CytoSorb® Blood Purification (PR Newswire)
01-10-2018
Your Daily Pharma Scoop: Aradigm Sees Sell-Off Ahead Of Ad Com, Editas Provides Update, Axsome Suffers Setback (SeekingAlpha)
01-08-2018
CytoSorbents Pre-Announces Preliminary Fourth Quarter and Full Year 2017 Results and Issues Stockholder Letter (PR Newswire)
01-03-2018
CytoSorbents To Provide Corporate Update at Biotech Showcase 2018 (PR Newswire)
12-22-2017
Biotech Forum Daily Digest: Synergy's CEO Leaves, Shareholders Cheer! (SeekingAlpha)
12-21-2017
CytoSorbents on go with pivotal study of CytoSorb in cardiac surgery; shares up 4% (SeekingAlpha)
12-21-2017
CytoSorbents Achieves Key Milestone with FDA Approval of the U.S. REFRESH 2 Pivotal Cardiac Surgery Trial IDE Application (PR Newswire)
12-19-2017
CytoSorbents Receives $676,739 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program (PR Newswire)


Smart Money Sentiment

Institutional Ownership (Top 15 Funds) 8.4%

Earnings Stats

PE Ratio -24.53
Dividend Yield 0%
Peer EarningsEarnings Calendar

Technicals

200 Day Moving Average $5.72
50 Day Moving Average $7.12
52 Week High $8.1
52 Week Low $3.3



Data provided for free by IEX. Questions? Read the FAQ